Vinorelbine and Oligohydramnios - a phase IV clinical study of FDA data

Summary:

Oligohydramnios is found among people who take Vinorelbine, especially for people who are 30-39 old.

The phase IV clinical study analyzes which people take Vinorelbine and have Oligohydramnios. It is created by eHealthMe based on reports of 5,229 people who have side effects when taking Vinorelbine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Sep, 29, 2022

5,229 people reported to have side effects when taking Vinorelbine.
Among them, 7 people (0.13%) have Oligohydramnios.


What is Vinorelbine?

Vinorelbine has active ingredients of vinorelbine. eHealthMe is studying from 5,235 Vinorelbine users for its effectiveness, alternative drugs and more.

What is Oligohydramnios?

Oligohydramnios (a condition in pregnancy characterized by a deficiency of amniotic fluid) is found to be associated with 602 drugs and 415 conditions by eHealthMe.

Number of Vinorelbine and Oligohydramnios reports submitted per year:

Could Vinorelbine cause Oligohydramnios?

Age of people who have Oligohydramnios when taking Vinorelbine *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 83.33 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 16.67 %

Common drugs people take besides Vinorelbine *:

  1. Ibandronate Sodium: 2 people, 28.57%
  2. Valproic Acid: 1 person, 14.29%
  3. Mistletoe: 1 person, 14.29%
  4. Levetiracetam: 1 person, 14.29%
  5. Herceptin: 1 person, 14.29%

Common side effects people have besides Oligohydramnios *:

  1. Normal Newborn: 2 people, 28.57%
  2. Maternal Exposure During Pregnancy (use of substance during pregnancy): 2 people, 28.57%
  3. Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 2 people, 28.57%
  4. Premature Labor: 1 person, 14.29%
  5. Premature Baby: 1 person, 14.29%
  6. Oedema (fluid collection in tissue): 1 person, 14.29%
  7. Hemiparesis (weakness on one side of the body): 1 person, 14.29%
  8. Foetal Hypokinesia (decreased bodily movement of foetus): 1 person, 14.29%
  9. Fatigue (feeling of tiredness): 1 person, 14.29%
  10. Convulsive Threshold Lowered: 1 person, 14.29%

Common conditions people have *:

  1. Breast Cancer Metastatic: 6 people, 85.71%
  2. Metastases To Spine (cancer spreads to spine): 2 people, 28.57%
  3. Small Cell Lung Cancer Metastatic (lung cancer spreads to other body parts): 1 person, 14.29%
  4. Breast Cancer: 1 person, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Vinorelbine and have Oligohydramnios?

Check whether Oligohydramnios is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

How severe was Oligohydramnios and when was it recovered:

Expand to all the drugs that have ingredients of vinorelbine:

Alternative drugs to, pros and cons of Vinorelbine:

Common Vinorelbine side effects:

Browse all side effects of Vinorelbine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Oligohydramnios treatments and more:

COVID vaccines that are related to Oligohydramnios:

Common drugs associated with Oligohydramnios:

All the drugs that are associated with Oligohydramnios:

Common conditions associated with Oligohydramnios:

All the conditions that are associated with Oligohydramnios:

How the study uses the data?

The study uses data from the FDA. It is based on vinorelbine (the active ingredients of Vinorelbine) and Vinorelbine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: